Healthcare [ 10/13 ] | Biotechnology [ 103/159 ]
NASDAQ | Common Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 29, 23 | -0.42 Decreased by -16.67% | -0.38 Decreased by -10.53% |
Aug 31, 23 | -1.48 Decreased by -92.21% | -0.93 Decreased by -59.14% |
May 31, 23 | -0.38 Increased by +28.3% | -0.38 |
Mar 28, 23 | -1.55 Decreased by -229.79% | -0.4 Decreased by -287.5% |
Nov 30, 22 | -0.36 Decreased by -33.33% | -0.36 |
Aug 30, 22 | -0.77 Decreased by -28.33% | -0.53 Decreased by -45.28% |
Jun 1, 22 | -0.53 Increased by +13.11% | -0.53 |
Mar 31, 22 | -0.47 Increased by +69.68% | -0.32 Decreased by -46.87% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Jun 30, 23 | 17.3 M Increased by +N/A% | -4.11 M Decreased by N/A% | Decreased by -23.76% - |
Mar 31, 23 | 5.35 M Decreased by -42.55% | -32.18 M Increased by +24.54% | Decreased by -602.08% Decreased by -31.34% |
Dec 31, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
Sep 30, 22 | 2.68 M Increased by +N/A% | -16.16 M Decreased by N/A% | Decreased by -602.08% - |
Jun 30, 22 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
Mar 31, 22 | 9.3 M Increased by +5.36 K% | -42.65 M Decreased by -423.18% | Decreased by -458.43% Decreased by -105.92% |
Dec 31, 21 | N/A Decreased by -100% | N/A Decreased by -100% | - - |
Sep 30, 21 | N/A Decreased by N/A% | N/A Increased by +100% | - - |
Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.